ME02348B - POSTUPAK ZA PRIPREMU ESTARA (5-FLUORO-2-METIL-3-HINOLIN-2-lL METIL-INDOL-1-IL)-SIRĆETNE KISELINE - Google Patents
POSTUPAK ZA PRIPREMU ESTARA (5-FLUORO-2-METIL-3-HINOLIN-2-lL METIL-INDOL-1-IL)-SIRĆETNE KISELINEInfo
- Publication number
- ME02348B ME02348B MEP-2015-218A MEP2015218A ME02348B ME 02348 B ME02348 B ME 02348B ME P2015218 A MEP2015218 A ME P2015218A ME 02348 B ME02348 B ME 02348B
- Authority
- ME
- Montenegro
- Prior art keywords
- formula
- compound
- iii
- reaction
- process according
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 19
- 238000002360 preparation method Methods 0.000 title claims 3
- FATGTHLOZSXOBC-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid Chemical class C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1CC1=CC=C(C=CC=C2)C2=N1 FATGTHLOZSXOBC-UHFFFAOYSA-N 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 16
- 238000006243 chemical reaction Methods 0.000 claims 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011541 reaction mixture Substances 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- 230000007062 hydrolysis Effects 0.000 claims 3
- 238000006460 hydrolysis reaction Methods 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- JJIUISYYTFDATN-UHFFFAOYSA-N 5-fluoro-2-methyl-1h-indole Chemical compound FC1=CC=C2NC(C)=CC2=C1 JJIUISYYTFDATN-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 239000012535 impurity Substances 0.000 claims 2
- WPYJKGWLDJECQD-UHFFFAOYSA-N quinoline-2-carbaldehyde Chemical compound C1=CC=CC2=NC(C=O)=CC=C21 WPYJKGWLDJECQD-UHFFFAOYSA-N 0.000 claims 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims 1
- 229910000024 caesium carbonate Inorganic materials 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201121557A GB201121557D0 (en) | 2011-12-15 | 2011-12-15 | Process |
| EP12805725.4A EP2791129B1 (en) | 2011-12-15 | 2012-12-14 | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters |
| PCT/GB2012/000903 WO2013088108A1 (en) | 2011-12-15 | 2012-12-14 | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02348B true ME02348B (me) | 2016-06-20 |
Family
ID=45560499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-218A ME02348B (me) | 2011-12-15 | 2012-12-14 | POSTUPAK ZA PRIPREMU ESTARA (5-FLUORO-2-METIL-3-HINOLIN-2-lL METIL-INDOL-1-IL)-SIRĆETNE KISELINE |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9102658B2 (enExample) |
| EP (1) | EP2791129B1 (enExample) |
| JP (2) | JP6300277B2 (enExample) |
| KR (1) | KR102018929B1 (enExample) |
| CN (1) | CN104114548B (enExample) |
| AU (1) | AU2012351341B2 (enExample) |
| BR (1) | BR112014014604B1 (enExample) |
| CA (1) | CA2859281C (enExample) |
| CY (1) | CY1117087T1 (enExample) |
| DK (1) | DK2791129T3 (enExample) |
| EA (1) | EA026617B1 (enExample) |
| ES (1) | ES2557762T3 (enExample) |
| GB (1) | GB201121557D0 (enExample) |
| HR (1) | HRP20151422T1 (enExample) |
| HU (1) | HUE028257T2 (enExample) |
| IL (1) | IL233132A (enExample) |
| ME (1) | ME02348B (enExample) |
| MX (1) | MX342273B (enExample) |
| PL (1) | PL2791129T3 (enExample) |
| PT (1) | PT2791129E (enExample) |
| RS (1) | RS54523B1 (enExample) |
| SG (1) | SG11201402798RA (enExample) |
| SI (1) | SI2791129T1 (enExample) |
| SM (1) | SMT201500327B (enExample) |
| UA (1) | UA111868C2 (enExample) |
| WO (1) | WO2013088108A1 (enExample) |
| ZA (1) | ZA201404246B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| WO2020136093A1 (en) | 2018-12-27 | 2020-07-02 | Chiesi Farmaceutici S.P.A. | Process for preparing spherical agglomerates of timapiprant |
| CN111978245A (zh) * | 2020-09-15 | 2020-11-24 | 上海毕得医药科技有限公司 | 一种3-氟-2-异丁基吡啶的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007508363A (ja) | 2003-10-14 | 2007-04-05 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB0504150D0 (en) * | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| US7188489B2 (en) | 2005-04-12 | 2007-03-13 | Martello Russell A | Portable air conditioner |
| GB0605743D0 (en) | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
| ES2391671T3 (es) | 2006-07-22 | 2012-11-28 | Oxagen Limited | Compuestos con actividad antagonista de CRTH2 |
| US20110124683A1 (en) | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| DK2250161T3 (da) | 2008-01-18 | 2014-01-27 | Atopix Therapeutics Ltd | Forbindelser med CRTH2-antagonistaktivitet |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| EP2240444A1 (en) | 2008-01-22 | 2010-10-20 | Oxagen Limited | Compounds having crth2 antagonist activity |
| WO2009093026A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| CN104114169A (zh) | 2011-12-16 | 2014-10-22 | 阿托佩斯治疗有限公司 | 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 |
-
2011
- 2011-12-15 GB GB201121557A patent/GB201121557D0/en not_active Ceased
-
2012
- 2012-12-14 RS RS20150871A patent/RS54523B1/sr unknown
- 2012-12-14 UA UAA201406835A patent/UA111868C2/uk unknown
- 2012-12-14 BR BR112014014604-7A patent/BR112014014604B1/pt not_active IP Right Cessation
- 2012-12-14 CA CA2859281A patent/CA2859281C/en active Active
- 2012-12-14 JP JP2014546621A patent/JP6300277B2/ja not_active Expired - Fee Related
- 2012-12-14 US US14/364,509 patent/US9102658B2/en not_active Expired - Fee Related
- 2012-12-14 DK DK12805725.4T patent/DK2791129T3/en active
- 2012-12-14 ES ES12805725.4T patent/ES2557762T3/es active Active
- 2012-12-14 SI SI201230408T patent/SI2791129T1/sl unknown
- 2012-12-14 PT PT128057254T patent/PT2791129E/pt unknown
- 2012-12-14 EA EA201490998A patent/EA026617B1/ru unknown
- 2012-12-14 SG SG11201402798RA patent/SG11201402798RA/en unknown
- 2012-12-14 PL PL12805725T patent/PL2791129T3/pl unknown
- 2012-12-14 WO PCT/GB2012/000903 patent/WO2013088108A1/en not_active Ceased
- 2012-12-14 EP EP12805725.4A patent/EP2791129B1/en active Active
- 2012-12-14 HR HRP20151422TT patent/HRP20151422T1/hr unknown
- 2012-12-14 HU HUE12805725A patent/HUE028257T2/en unknown
- 2012-12-14 KR KR1020147017740A patent/KR102018929B1/ko not_active Expired - Fee Related
- 2012-12-14 AU AU2012351341A patent/AU2012351341B2/en not_active Ceased
- 2012-12-14 MX MX2014007129A patent/MX342273B/es active IP Right Grant
- 2012-12-14 ME MEP-2015-218A patent/ME02348B/me unknown
- 2012-12-14 CN CN201280066207.8A patent/CN104114548B/zh not_active Expired - Fee Related
-
2014
- 2014-06-09 ZA ZA2014/04246A patent/ZA201404246B/en unknown
- 2014-06-15 IL IL233132A patent/IL233132A/en active IP Right Grant
-
2015
- 2015-12-23 SM SM201500327T patent/SMT201500327B/it unknown
- 2015-12-23 CY CY20151101189T patent/CY1117087T1/el unknown
-
2017
- 2017-07-28 JP JP2017146700A patent/JP2018008985A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151422T1 (hr) | Postupak za pripremu estera (5-fluoro-2-metil-3-hinolin-2-ilmetil-indol-1-il)-octene kiseline | |
| CN102603607B (zh) | （r）-奥拉西坦的制备方法 | |
| US8338645B2 (en) | Method for producing a β-alkoxypropionamide | |
| UA102386C2 (ru) | Способ получения алкил-2-алкоксимэтилен-4,4-дифтор-3-оксобутиратов | |
| CN103274959B (zh) | 一种凉味剂n,2,3-三甲基-2-异丙基丁酰胺的合成方法 | |
| HRP20160241T1 (hr) | Postupci i intermedijeri za pripravu jak inhibitora | |
| MX351176B (es) | Método para producir y purificar sales del ácido acrilamido-2- metilpropan sulfónico. | |
| MX2020010367A (es) | Procedimiento para la preparación de iopamidol. | |
| JP2015500325A5 (enExample) | ||
| CN103232369B (zh) | 一种芴甲氧羰酰谷氨酸-5-叔丁酯的制备方法 | |
| WO2016024284A2 (en) | A process for the preparation of mirabegron and its intermediates | |
| HRP20120958T1 (hr) | Postupci za pripremanje supstituirane gama-aminokiseline | |
| CN101891686A (zh) | N-β-丙氨酰-(τ-甲基)组氨酸的合成方法 | |
| HRP20110322T1 (hr) | Postupak za pročišćavanje montelukasta | |
| JP6726801B2 (ja) | 式ｉｉで表されるアビバクタム調製用材料化合物の調製方法 | |
| IN2013MN02407A (enExample) | ||
| HRP20120501T1 (hr) | Postupak proizvodnje 4'-[[4-metil-6-(1-metil-1h-benzimidazol-2-il)-2-propil-1h-benzimidazol-1-il]metil]bifenil-2-karboksilne kiseline (telmisartan) | |
| US9290432B2 (en) | Process for the preparation of travoprost | |
| CN114315866A (zh) | 一种盐酸左旋咪唑的合成方法 | |
| CN112939814B (zh) | 一种氘代达卡他韦中间体的制备方法 | |
| HRP20160407T1 (hr) | Postupak za pripravu skopin estera di-(2-tienil) glikolne kiseline, međuprodukta u sintezi tiotropij bromida | |
| CN106946724A (zh) | 单胺基抑制剂类中间体2‑乙酰氨基‑2‑苄基丙二酸单乙酯的合成方法 | |
| CN104592028A (zh) | 橡胶增塑剂邻苯二甲酸二丁酯的制备方法 | |
| RU2658916C1 (ru) | Способ получения 2-амино-6-метилникотиновой кислоты | |
| US7265238B2 (en) | Process for preparing methyl 4-(aminomethyl)benzoate |